
Camlin Fine Sciences Q1 Results FY27: What to Expect
Camlin Fine Sciences Q1 Results FY27: Revenue Rs 472 Cr (+11.3% YoY) | PAT Rs -6 Cr (-50.0% YoY), Uniresearch estimate.
Updated: 29 Jun 2026 • 2:30 pm
Posted by:

Camlin Fine Sciences Q1 Results FY27 prediction is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. Camlin Fine Sciences reported Revenue of Rs 424 Cr and PAT of Rs -11 Cr in Q1 FY26, forming the base for the Camlin Fine Sciences Q1 Results FY27 forecast of Rs 472 Cr Revenue and Rs -6 Cr PAT. Prepared by Kunal Singla, Associate Director.
Click Here – Get Free Investment Predictions
Camlin Fine Sciences Q1 Results FY27: Uniresearch Prediction
| Metric | Q1 FY26 Actual | Q1 FY27 Uniresearch Prediction | YoY Change |
|---|---|---|---|
| Revenue (Rs Cr) | 424 | 472 | +11.3% |
| PAT (Rs Cr) | -11 | -6 | -50.0% |
Source: Q1 FY26 actuals from Screener.in consolidated quarterly financial data. Q1 FY27 prediction for Camlin Fine Sciences applies Uniresearch trailing growth rates (Revenue +11.3%, PAT -50.0%) to Q1 FY26 verified actuals.
Track Camlin Fine Sciences Live on Univest Screener
Q4 FY26 Performance: Base for the Prediction
The Camlin Fine Sciences Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 425 Cr and PAT of Rs 86 Cr per quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection.
The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 425 Cr reflects year-end execution cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 424 Cr, where the Uniresearch estimate targets +11.3% growth. Both reads should be monitored when the actual Q1 FY27 numbers are declared.
Uniresearch Estimate Behind the Camlin Fine Sciences Q1 Results FY27 Projection
The Camlin Fine Sciences Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of +11.3% and PAT growth of -50.0% year-on-year. Uniresearch applies these trailing growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 472 Cr Revenue and Rs -6 Cr PAT.
The Q1 FY27 estimation methodology for Camlin Fine Sciences is worth clarifying for investors. Uniresearch applies full-year FY27 trailing growth rates (+11.3% Revenue, -50.0% PAT) uniformly to Q1 FY26 verified actuals to derive the quarterly projection. This approach assumes the quarterly trajectory broadly mirrors the full-year trend direction. Intra-year seasonality and one-time events can cause divergence. Treat this Q1 FY27 Uniresearch estimate for Camlin Fine Sciences as a directional benchmark, not a point forecast.
Get Expert Stock Picks on Univest
Key Watchpoints for the Camlin Fine Sciences Q1 Results FY27
Revenue vs Estimate
Whether Camlin Fine Sciences Q1 Results FY27 Revenue delivers in line with the Rs 472 Cr Uniresearch estimate (+11.3% YoY). Q4 FY26 Revenue was Rs 425 Cr.
PAT Margin Sustainability
PAT of Rs -6 Cr (-50.0% YoY) is the Camlin Fine Sciences Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 86 Cr. Margin stability signals operating leverage.
Management Commentary and Full-Year FY27 Guidance
Beyond Q1 FY27 headline numbers, Camlin Fine Sciences’s management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook post an in-line result could support re-rating.
Risks to the Camlin Fine Sciences Q1 Results FY27 Prediction
Below-Estimate Revenue Growth
If actual Q1 FY27 Revenue underperforms the +11.3% growth target, the Rs 472 Cr prediction would be revised downward.
PAT Pressure from Costs or Provisions
One-time charges, higher input costs, or elevated provisions could push PAT below Rs -6 Cr.
External and Macro Environment
The Q1 FY27 performance is also exposed to macro-level risks including global commodity price movements, rupee-dollar volatility, domestic interest rate changes, and FII/DII sentiment shifts. A deteriorating macro environment in Q1 FY27 could create downside risk even if company-specific execution remains on track.
Camlin Fine Sciences Q1 Results FY27: Sector Growth Drivers
Sector positioning in the specialty chemicals and industrial chemicals sector. The following tailwinds and headwinds will shape the result.
Domestic Demand and Import Substitution
India’s specialty chemicals sector benefits from China-plus-one sourcing shifts and growing end-user demand.
Export Recovery and Realisation Improvement
Recovering export order books and easing feedstock costs support margin recovery.
Use Univest Screener to Track Camlin Fine Sciences Live
Camlin Fine Sciences Q1 Results FY27: Conclusion
The Camlin Fine Sciences Q1 Results FY27 Uniresearch projection of Revenue Rs 472 Cr and PAT Rs -6 Cr is derived from trailing growth rates applied to Q1 FY26 actuals. Track Camlin Fine Sciences live on the Univest Screener for real-time updates.
Once the actual Q1 FY27 result for Camlin Fine Sciences is declared, compare it directly against the Uniresearch estimate to assess beat, meet, or miss. Use Univest research and screener tools to stay updated post the result announcement and to track any revision to the full-year FY27 outlook.
Download the Univest iOS App or Univest Android App for live Q1 FY27 result alerts.
Disclaimer: Revenue and PAT actuals sourced from Screener.in consolidated quarterly financial data. Q1 FY27 projections are derived from Uniresearch trailing growth rates applied to Q1 FY26 actuals. These are Uniresearch trailing estimates, not guaranteed outcomes. Investments are subject to market risk. For educational purposes only. SEBI RA INH000013776.
Frequently Asked Questions on Camlin Fine Sciences Q1 Results FY27
What is the Uniresearch prediction for Camlin Fine Sciences Q1 Results FY27?
Ans. Uniresearch projects Q1 FY27 Revenue for Camlin Fine Sciences at Rs 472 Cr (+11.3% YoY) and PAT at Rs -6 Cr (-50.0% YoY), based on trailing analysis of Q1 FY26 actuals. Q1 FY26 Revenue was Rs 424 Cr and PAT Rs -11 Cr. Treat as directional estimate.
What growth rate assumptions are used in the Uniresearch estimate for Camlin Fine Sciences Q1 Results FY27?
Ans. The Uniresearch estimate applies trailing YoY growth rates (Revenue +11.3%, PAT -50.0%) derived from historical quarterly data to Q1 FY26 actuals (Revenue Rs 424 Cr, PAT Rs -11 Cr). These are directional estimates, not guarantees.
What were the Q4 FY26 actuals behind the Camlin Fine Sciences Q1 Results FY27 projection?
Ans. Q4 FY26 consolidated Revenue was Rs 425 Cr and PAT was Rs 86 Cr. These Q4 FY26 actuals serve as the most recent sequential reference alongside the Q1 FY26 base.
How reliable is the Camlin Fine Sciences Q1 Results FY27 Uniresearch prediction?
Ans. The Q1 Results FY27 estimate is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark and compare against declared actuals on the Univest Screener.
What base data is used for the Camlin Fine Sciences Q1 Results FY27 Uniresearch projection?
Ans. The Q1 FY27 projection for Camlin Fine Sciences uses Q1 FY26 consolidated actuals (Revenue Rs 424 Cr, PAT Rs -11 Cr) from Screener.in quarterly data. Trailing growth rates (+11.3% Revenue, -50.0% PAT) are applied to derive the Q1 FY27 estimate.
What are the key risks to the Camlin Fine Sciences Q1 Results FY27 estimate?
Ans. Key risks to the Q1 Results FY27 estimate for Camlin Fine Sciences include feedstock cost sensitivity, chinese competition, and broader macro headwinds. Any of these could cause actual Q1 FY27 Revenue or PAT to undershoot the Uniresearch projection.
When will Camlin Fine Sciences declare the actual Camlin Fine Sciences Q1 Results FY27 data?
Ans. Camlin Fine Sciences will declare Q1 FY27 results after Q1 FY27 ends, typically shortly after Q1 FY27 ends. The board meeting date will be disclosed via NSE or BSE filings. Track live updates on the Univest Screener.
Recent Articles

Radiant Cash Management Services Share Price Target 2026 Analyst Forecast Bull and Bear Case
29 June 2026

Pfizer India Q1 Results FY27: What to Expect
29 June 2026

PVP Ventures Share Price Target 2026 Analyst Forecast Bull and Bear Case
29 June 2026

Rajratan Global Wire Share Price Target 2026 Analyst Forecast Bull and Bear Case
29 June 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Radiant Cash Management Services Share Price Target 2026 Analyst Forecast Bull and Bear Case
Pfizer India Q1 Results FY27: What to Expect
PVP Ventures Share Price Target 2026 Analyst Forecast Bull and Bear Case
Rajratan Global Wire Share Price Target 2026 Analyst Forecast Bull and Bear Case
Why Is SECUREKLOUD TECHNOLOGIES Share Price Falling Key Reasons 2026
Popular this week
Radiant Cash Management Services Share Price Target 2026 Analyst Forecast Bull and Bear Case
Pfizer India Q1 Results FY27: What to Expect
PVP Ventures Share Price Target 2026 Analyst Forecast Bull and Bear Case
Rajratan Global Wire Share Price Target 2026 Analyst Forecast Bull and Bear Case
Why Is SECUREKLOUD TECHNOLOGIES Share Price Falling Key Reasons 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





